Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 22, 2015

Primary Completion Date

May 7, 2018

Study Completion Date

May 7, 2018

Conditions

Autism Spectrum Disorder

Interventions

DRUG

Ketamine

Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator

DRUG

Placebo

Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator

Trial Locations (1)

Cincinnati Childrens Hospital Medical Center, Cincinnati

All Listed Sponsors

collaborator

Roivant Sciences, Inc.

INDUSTRY

collaborator

Cures Within Reach

OTHER

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT02611921 - Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder | Biotech Hunter | Biotech Hunter